Ibrance is indicated for the treatment of patients with hormone receptor positive, human epidermal growth factor receptor 2 negative advanced or metastatic breast cancer in combination with an aromatase inhibitor as initial endocrine-based therapy; or fulvestrant in patients with disease progression following endocrine therapy.1

Real-world Experience

What is RWD and RWE IBRANCE RWE Initiatives FlatironIRIS
PALOMA was the first clinical trial programme to investigate how a CDK4/6 inhibitor might benefit women with HR+/HER2-ABCand is now also the first to be supported by RWE3
ABC = advanced breast cancer; CDK = cyclin-dependent kinase; EMA = European Medicines Agency; ET = endocrine therapy;
FDA = Food and Drug Administration; HR+/HER2- = hormone receptor-positive, human epidermal growth factor receptor 2-negative;
mBC = metastatic breast cancer, RCT = randomised controlled trial; RWE = real-world evidence.



IBRANCE has been evaluated in 3 RCTs in ~1300 women with HR+/HER2- advanced or mBC as part of Pfizer’s robust PALOMA Clinical Trial Programme4-6
ABC = advanced breast cancer; ER+/HER2 - = estrogen receptor-positive, human epidermal growth factor receptor 2-negative; ET = endocrine therapy; HR+/HER2- = hormone receptor positive, human epidermal growth factor receptor 2-negative; mBC = metastatic breast cancer; RCT = randomised controlled trial.


Multiple ongoing real-world studies at varied geographic locations13-20
EHR = electronic health record; PRO = patient-reported outcome; RWE = real-world evidence.

​​​​​​​

References

  1. IBRANCE® (Palbociclib) Prescribing Information. Available from: http://labeling.pfizer.com/ShowLabeling.aspx?id=12240. Accessed September 10, 2021.
  2. McCain J. P T. 2015;40(8):511-520.
  3. IBRANCE Data on File.
  4. Finn RS, et al. Lancet Oncol. 2015;16(1):25-35.
  5. Finn RS, et al. N Engl J Med. 2016;375(20):1925-1936.
  6. Cristofanilli M, et al. Lancet Oncol. 2016;17(4):425-439.
  7. Clinical trials.gov. Available at: https://clinicaltrials.gov/ct2/show/NCT00721409. Accessed May 2020.
  8. Clinical trials.gov. Available at: https://clinicaltrials.gov/ct2/show/NCT01740427. Accessed May 2020.
  9. Clinical trials.gov. Available at: https://clinicaltrials.gov/ct2/show/NCT01942135. Accessed May 2020.
  10. Palbociclib (IBRANCE) US Food and Drug Administation. Resources for Information. Approved drugs. Available at: https://www.fda.gov/drugs/resources-information-approved-drugs/palbociclib-ibrance. Accessed May 2020.
  11. European Medicines Agency (EMEA). IBRANCE (palbociclib). Available at: https://www.ema.europa.eu/en/medicines/human/EPAR/ibrance. Accessed May 2020.
  12. IBRANCE (Palbociclib) Capsules FDA Supplement approval. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2019 /207103Orig1s008ltr.pdf. Accessed May 2020.
  13. DeMichele A, et al. SABCS 2019; Poster P1-19-02.
  14. Taylor-Stokes G, et al. Breast. 2019;43:22-27.
  15. Waller J, et al. J Glob Oncol. 2019;5:JGO1800239.
  16. Taylor-Stokes G, et al. ESMO Breast 2020; abstract.
  17. Blum JL, et al. Ann Oncol. 2018;29 (suppl_8):viii90-viii121.
  18. HarbeckN, et al. ESMO Breast 2019; poster 165P.
  19. Kim HS, et al. J Korean Med Sci. 2018;33(34):e213.
  20. Richardson D, et al. ASCO 2020; abstract.

Support and Services


Learn more ► 
Learn more ► 
Learn more ► 
All rights reserved. Date of preparation: June 2020 PP-IBR-GLB-0254

​​​​​​​Intended for Healthcare Professionals only.

© 2021 Pfizer Pte Ltd. All rights reserved.


The information provided in this site is intended only for Health Care Professionals in Singapore. The products discussed herein may have different product labelling in different countries. Pfizer Corporation Singapore Limited is a subsidiary of Pfizer Inc, a pharmaceutical company committed to helping people improve their health by discovering and developing medicines.